No­vo Nordisk of­floads pre­clin­i­cal can­cer can­di­date from $1.1B For­ma buy­out

When No­vo Nordisk first ap­proached For­ma Ther­a­peu­tics about a deal, the Dan­ish drug­mak­er made clear that it was re­al­ly on­ly in­ter­est­ed in For­ma’s sick­le cell …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER